Founded in 2002, Prollenium is a fast-growing Canadian company who operates as a developer, manufacturer and distributor of medical aesthetics products. The company’s product expertise and technical knowledge covers the field of facial aesthetics products, ingredients optimization and technical quality testing. Prollenium’s flagship product Revanesse is a line of cross-linked hyaluronic acid dermal fillers. In 2005, the business was granted approval to begin distribution of their first injectable dermal filler in Canada and in 2017 was granted FDA approval to sell in the US.